Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment Since the Date of Last Report Questions: 1 - 32

Anemia

yes no Unknown

1

(Hgb < 9 g/dL)

Degranulation assay of NK cells

Normal Abnormal Unknown

2

(as defined by local laboratory)

Fevers

yes no Unknown

3

(> 38.5° C or > 101.3° F for > 7 days)

Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

yes no Unknown

4

Serum ferritin

Known Unknown

5

6 µg/L

Triglycerides

Known Unknown

7

8 mg/dL mmol/L

Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

Known Unknown

9

10 g/dL mg/dL µmol/L g/L

NK cell function11

Absent (≤10% lower limit of normal)

Decreased (11-50% lower limit of normal)

Normal

Unknown

Neutropenia (ANC < 1.0 x 109 /L)

yes no Unknown

12

Soluble interleukin-2 receptor alpha chain (sCD25)

Normal Elevated Unknown

13

(as defined by local laboratory)

Splenomegaly (spleen palpable > 3 cm below left costal margin)

yes no Unknown

14

Thrombocytopenia (platelets < 100 x 109 /L)

yes no Unknown

15

Neopterin level

Normal Elevated Not done

16

Protein

Normal Elevated Not done

17

WBC count18

Normal (≤5 cells/µL)

Elevated (>5 cells/µL)

Not done

Were central nervous system (CNS) abnormalities found on a computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scan since the date of the last report?

yes no Unknown

19

Was documentation submitted to the CIBMTR?

yes no

20

(e.g. CT or MRI scan report)

Did any clinical neurologic abnormalities persist or develop?

yes no Unknown

21

Abnormal gait

yes no

22

Cranial nerve palsies

yes no

23

Developmental delay

yes no

24

Motor weakness

yes no

25

Seizures

yes no

26

Sensory deficits

yes no

27

Other neurologic abnormality

yes no

28

Specify other neurologic abnormality:29

Were there any signs of disease relapse / reactivation?

yes no

30

Specify the date of the relapse / reactivation:31 __ __ __ __ - __ __- __ __

Specify the site of the relapse / reactivation

CNS Systemic CNS and systemic

32

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT Type (check all that apply):

Product Type: (check all that apply)

Indicate which of the following clinical features and laboratory findings were present since the date of the last report: 

Specify the recipient's most current cerebrospinal fluid findings since the date of the last report: 

Specify neurologic abnormalities:

Center: CRID: 

Form 2139 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Post-HCT Data

CIBMTR Form 2139 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 1 / 2



Key Fields

Sequence Number:

Date Received: __ __ __ __ - __ __- __ __

CIBMTR Center Number:

CIBMTR Recipient ID:

Date of HCT for which this form is being completed: __ __ __ __ - __ __- __ __

Autologous

Allogeneic, unrelated

Allogeneic, related

Bone marrow

PBSC

Single cord blood unit

Multiple cord blood units

Other product

Specify:

Visit

100 day 6 months 1 year 2 years > 2 years,

Specify:

Disease Assessment Since the Date of Last Report Questions: 1 - 32

Anemia

yes no Unknown

1

(Hgb < 9 g/dL)

Degranulation assay of NK cells

Normal Abnormal Unknown

2

(as defined by local laboratory)

Fevers

yes no Unknown

3

(> 38.5° C or > 101.3° F for > 7 days)

Hepatomegaly (liver edge palpable > 3 cm below right costal margin)

yes no Unknown

4

Serum ferritin

Known Unknown

5

6 µg/L

Triglycerides

Known Unknown

7

8 mg/dL mmol/L

Fibrinogen antigen assay (factor I; fibrinogen activity; functional fibrinogen; fibrinogen antigen)

Known Unknown

9

10 g/dL mg/dL µmol/L g/L

NK cell function11

Absent (≤10% lower limit of normal)

Decreased (11-50% lower limit of normal)

Normal

Unknown

Neutropenia (ANC < 1.0 x 109 /L)

yes no Unknown

12

Soluble interleukin-2 receptor alpha chain (sCD25)

Normal Elevated Unknown

13

(as defined by local laboratory)

Splenomegaly (spleen palpable > 3 cm below left costal margin)

yes no Unknown

14

Thrombocytopenia (platelets < 100 x 109 /L)

yes no Unknown

15

Neopterin level

Normal Elevated Not done

16

Protein

Normal Elevated Not done

17

WBC count18

Normal (≤5 cells/µL)

Elevated (>5 cells/µL)

Not done

Were central nervous system (CNS) abnormalities found on a computed tomography (CT or CAT) or magnetic resonance imaging (MRI) scan since the date of the last report?

yes no Unknown

19

Was documentation submitted to the CIBMTR?

yes no

20

(e.g. CT or MRI scan report)

Did any clinical neurologic abnormalities persist or develop?

yes no Unknown

21

Abnormal gait

yes no

22

Cranial nerve palsies

yes no

23

Developmental delay

yes no

24

Motor weakness

yes no

25

Seizures

yes no

26

Sensory deficits

yes no

27

Other neurologic abnormality

yes no

28

Specify other neurologic abnormality:29

Were there any signs of disease relapse / reactivation?

yes no

30

Specify the date of the relapse / reactivation:31 __ __ __ __ - __ __- __ __

Specify the site of the relapse / reactivation

CNS Systemic CNS and systemic

32

First Name:

Last Name:

E-mail address:

Date: __ __ __ __ - __ __- __ __

HCT Type (check all that apply):

Product Type: (check all that apply)

Indicate which of the following clinical features and laboratory findings were present since the date of the last report: 

Specify the recipient's most current cerebrospinal fluid findings since the date of the last report: 

Specify neurologic abnormalities:

Center: CRID: 

Form 2139 R3.0: Hemophagocytic Lymphohistiocytosis (HLH) Post-HCT Data

CIBMTR Form 2139 revision 3.0 last updated October 2013
Copyright(c) 2012 National Marrow Donor Program and

The Medical College of Wisconsin, Inc. All rights reserved. Page 2 / 2